This paper shows that anti-CD19 CAR NK cells, when combined with targeted drugs, can improve outcomes for high-risk BCP-ALL. The authors highlight the potential of this approach for long-term remission and recommend further clinical evaluation. Read it here 👉https://bit.ly/3JfNMmz

The treatment landscape of hematologic malignancies is changing with a shift away from chemo- and radiotherapy towards targeted approaches and immunotherapies. The European Hematology Association (#EHA) has championed several activities, summarized in this Perspective.  👉https://bit.ly/4haRASx

Authors of this paper show that 8 weeks of vemurafenib plus rituximab leads to high complete remission and minimal toxicity in relapsed/refractory hairy-cell leukemia, confirming strong results in real-world clinical practice Read more about this study here 👉https://bit.ly/4nPh3Tf

🔬Podcast Episode!   Dr Anikó Sijs-Szabó & Roger Mulet Lázaro PhD join Dr. Charles de Bock to unpack the challenges of diagnosing & treating acute leukemias of ambiguous lineage #ALAL.  🎧 Listen now on all major platforms & read the full open-access article  https://bit.ly/4oeJo6w #Hematology

2025 has been a successful year for HemaSphere Journal!  1000+ manuscript submissions  increasing impact in the field  insightful graphical abstracts  another podcast season  ...and of course, excellent research! We extend a warm thank you to all authors, reviewers & readers ❤️

The 2024 International Symposium on Hodgkin Lymphoma workshop highlighted critical challenges and opportunities in the harmonization of clinical trial reporting for HL.  This Perspective highlights some of the takeaways and recommendations, read it on our website 👉https://bit.ly/46NxD1a

In this paper published in the November issue,  specific HLA genotypes and diversity influence chronic myeloid leukemia risk and treatment outcomes. Authors suggest HLA typing may help guide therapy choices and predict remission or relapse. Read more about it here👉https://bit.ly/3LG7RDt

Read the latest HemaTopics from Scientific Editor Stephen Hibbs: As the ability to detect deviations from the norm grows ever greater, we must remember that labelling and monitoring such deviations is only sometimes helpful.  👉https://bit.ly/4o6l468

🚨New! In this extended episode host Sci Ed Charles de Bock discusses #SCD w/ co-authors, covering both expert & lived-patient perspectives This episode is on our website & all major podcast platforms. Listen & enjoy casual, insightful discussions about #hematology research https://bit.ly/4nIhH68

Authors aimed to evaluate the impact of prior CD19-directed therapy on subsequent CD19-based treatment, focusing on the impact of prior CD19 CAR T on tafa/len efficacy, comparing CAR T-exposed versus CAR T-naïve patients receiving tafa/len.  Read more here👉https://bit.ly/3LKVxlr

The HemaSphere office at EHA will be closed Dec 24-Jan 4, while we take time to rest + gear up for 2026.  Our #openaccess content is always available www.hemaspherejournal.com Should you need immediate help, feel free to contact our colleagues at Wiley: hemasphere at wiley dot com

This Guidelines paper recommends prioritizing CAR T-cell therapy over bispecific antibodies or ADCs for eligible relapsed/refractory myeloma patients, as prior use of certain agents may reduce CAR T-cell effectiveness.  👉https://bit.ly/4rn5d5K

In this paper authors present a new RNA-based model that improves risk assessment for infant AML. The authors show it outperforms previous methods and can guide more precise treatment decisions, especially regarding stem cell transplantation. Read more 👉https://bit.ly/43SOq0i

HemaTopics are HemaSphere pubs focusing on 🔥 heme topics. The latest by Sci Ed C de Bock, discusses 2 studies showing that combining menin inhibitors w/ KAT6/7 inhibitors may help overcome resistance in high-risk #AML, offering a promising approach for pts https://bit.ly/49u8BW5

New research uncovers how anthracyclines epigenetically upregulate ALDH1 isoforms, as adaptive response in AML and that dual ALDH1A1/1A2 inhibition has anti-leukemic activity Read it here 👉https://bit.ly/47zh9IL

📚 Never stop learning with HemaSphere Journal! Access high-quality hematology publications, always #OpenAccess.  Our current issue in progress can always be found here 👉https://bit.ly/3GIlBvj  #OpenAccess #MedicalEducation #CareerDevelopment

This paper shows that while corticosteroids are safe for managing CAR-T cell therapy side effects in large B-cell lymphoma, higher doses may increase infection risk and late blood toxicity. Judicious use is advised for optimal patient outcomes Read more about it 👉https://bit.ly/4rnh6J1

Podcast Playlists 📺 We've compiled our recommended podcasts into an easy-to-browse playlist format. Explore our current podcast selections organized by series. Even easier, start with the Top 5 Trending!  You've read the paper, now hear the story.  Top 5 monthly:  https://bit.ly/453lYcF

Comprehensive molecular sequencing at the institutional level can identify actionable biomarkers in most pediatric and #AYA leukemia cases, supporting more precise risk assessment and targeted therapies to improve patient outcomes. 👉https://bit.ly/4op13rv

This consensus Guidelines paper assesses whether next-generation sequencing (#NGS) could complement or even replace fluorescence in situ hybridization (FISH) at diagnosis. 👉https://bit.ly/4n7iPPx

Our December issue is now open!  The first papers have been published, have you seen them? https://bit.ly/44MwULI

Authors show that patients with IDH-mutated myeloid neoplasms and immune-mediated inflammatory disorders respond well to targeted IDH inhibitors, improving both blood and inflammatory symptoms. This approach may offer new treatment options. Read here👉https://bit.ly/3K08fMK #MN

Relapse after CD19-CAR T-cell therapy in B-cell #ALL is common, with early B-cell recovery signaling higher risk. An international group has now set consensus criteria for BCR to standardize monitoring and improve post-therapy care in this recent Guidelines paper. 👉https://bit.ly/3WO8gpR

Greetings from #ASH25. We already tested the nap pods for you 😅 Outcomes were very encouraging so we will try again today to increase the sample size of this new unofficial study. Have a great opening ASH day, everybody! #WhoNeedsJetLag #ASHScavengerHunt #HemaSphereHumans

🚨New! In this extended episode host Sci Ed Charles de Bock discusses #SCD w/ co-authors, covering both expert & lived-patient perspectives This episode is on our website & all major podcast platforms. Listen & enjoy casual, insightful discussions about #hematology research https://bit.ly/4nIhH68

#HemaSphere is heading to #ASH25 Are you interested to learn more? Looking to discuss your manuscript? Curious about who we are? Reach out - we can set a meeting time. Jessica will also be available at the #EHA booth (1482) at various times. See you in Orlando!

This newly published paper presents a rapid, accurate diagnostic method for hemoglobinopathies. The authors combine high-throughput proteomics and machine learning, offering a scalable alternative to traditional tests for hereditary anemias.  Read more 👉 https://bit.ly/3XuVSep

🩸 Fresh in HemaSphere Vol. 9(11): . Explore cutting-edge hematology research in our recent November issue! 👉https://bit.ly/44KWY9U

APCs will change as of January 1, 2026 submissions. This new rate is for the '26 & '27 calendar years.   HemaSphere’s 2026-2027 APCs remain competitively priced at: • Tier 1 - Articles, Review Articles, Guidelines: €2500 • Tier 2 - Perspectives, Letters: €1500 • Tier 3 - Editorials, Comments: €0

🚨Here's a sneak peak of the newest episode, which is based on a must-read Perspective "Can health inequalities in sickle cell disease be addressed through novel therapies?"  Host Charles de Bock discusses #SCD with co-authors: experts & patient perspective. 📺

This recently published paper highlights that while CAR T-cell therapy processes are broadly aligned, differences in implementation across manufacturers create inefficiencies and duplicate oversight, increasing hospital workload and diverting focus from patient care 👉https://bit.ly/4htzxXT

👉https://bit.ly/4oCBJii This paper show that ibrutinib not only reduces tumor B-cell activity in Waldenström’s macroglobulinemia, but also helps restore T-cell function. The authors suggest combining B-cell targeting with T-call reactivation may offer new treatment options.

💽 This paper presents new machine learning-based risk scores for newly diagnosed multiple myeloma. The authors show these models predict patient outcomes more accurately than traditional methods, supporting more personalized care decisions Read more in detail here 👉https://bit.ly/4ogHty5

HemaTopics discuss 🔥 heme news. Read this latest from Scientific Editor S Hibbs. After a pulmonary embolism, recovery isn’t only medical. The language clinicians use can either ease or amplify fear, anxiety & hypervigilance. Words are the first therapeutic intervention👉https://bit.ly/3Wp8C67

Abstract submissions for HExaT 2026 close 15 December! Attend the 3-day event on the Advances in Experimental and Therapeutic Haematopoietic Stem Cell Expansion taking place in York, UK 22-24 April, 2026. ISEH members receive discounted registration. Details: sites.google.com/york.ac.uk/h...

Baseline immune cell profiles, not just frailty, strongly predict survival in older multiple myeloma patients starting first-line therapy, highlighting the value of immune risk scores for prognosis. 👉https://bit.ly/47WK8aS

Replay! Host Dr Charles de Bock discusses research on #MDS w/ Dr Francesca Tiso & Dr Florentien in 't Hout. It covers the clinical presentation of MDS, treatment options & the significance of genetic mutations. “High 5hmC predicts worse OS”  https://bit.ly/3JGEq3C & all major podcast platforms.

🔬 Dive into the latest research with @Hemasphere_EHA! Our open access articles provide ground-breaking insights into #hematology. Stay ahead in your field and collaborate with peers. Our latest issue in progress can always be found here 👉 http://bit.ly/3GIlBvj #Research #OpenAccess

This recent paper shows that an online psychological group intervention for inpatients undergoing allo-HSCT is feasible & well accepted. Authors show it may help protect against depression & anxiety during hospitalization, supporting further research. Read more here 👉https://bit.ly/4oc4ulA

This recently published paper reports that isatuximab plus chemotherapy showed initial efficacy in children with relapsed acute leukemia, but complete response rates did not meet criteria for further study. Toxicity was manageable👉https://bit.ly/4qyzM8l #Pediatric #Hematology

Replay! Scientific Editor Dr Charles de Bock hosts Dr Thomas Mercher & Dr Alexandre Fagnan in this episode highlighting ETO2 activated gene transcription and how this affects erythroleukemia.  This episode is on our website and all major podcast platforms 🎧 https://bit.ly/3WNmEyA

📰Explore the newly released #EHAGuidelines for mantle cell lymphoma (#MCL) in HemaSphere. Developed by leading experts, these guidelines offer insight into treatment approaches, emerging non-chemo combinations, and innovations in relapsed/refractory care 👉https://bit.ly/47gdpLV

HemaTopics are HemaSphere publications focusing on 🔥 hematology topics. This week we focus on the latest HemaTopic by Scientific Editor L Merz, discussing the updated #CTCAE v6 & how the changes better reflect genetic diversity, such as the Duffy null variant 👉https://bit.ly/3LbIetU

🔬 This Comment to a recent HemaSphere paper highlights that the ELN Scoring System shows high sensitivity & specificity in diagnosing #MDS and #CMML, validated across large cohorts.  👉https://bit.ly/4nzRB4U Original article  📰https://bit.ly/4kVm8cv

This recent article reports that combining venetoclax with full-dose CPX-351 led to high remission rates and enabled most newly diagnosed AML patients, even those with high-risk features, to proceed to stem cell transplant safely.  Read more in our October issue 📖 https://bit.ly/3IV6zDK

🔬 New Podcast!   Dr Anikó Sijs-Szabó & Roger Mulet Lázaro PhD join Dr. Charles de Bock to unpack the challenges of diagnosing & treating acute leukemias of ambiguous lineage #ALAL.  🎧 Listen now on all major platforms & read the full open-access article  https://bit.ly/4oeJo6w #Hematology

This recent paper shows about 10% of recent hematology trials use eligibility criteria that may exclude people with the Duffy null variant. The authors recommend adjusting trial designs to ensure fair inclusion of all patient groups.  Read more in depth here 👉https://bit.ly/4qemD4j

📢 The November issue is now open! Opening the issue: Integrating transcriptomic profiling & machine learning for a clinically actionable prognostic model in infant AML. Read now 👉 https://bit.ly/43SOq0i #AML #MachineLearning #Transcriptomics

🩸 Fresh in HemaSphere Vol. 9(10): B-cell regulation in #WM, ISAKIDS trial, #CAR T-cell therapy burden, ALDH1 in AML, NGS in myeloma, HTLV-1 awareness, & more. Explore cutting-edge hematology! 📰https://bit.ly/4qOjoRm #HemaSphere #BloodCancer #Hematology

HTLV-1 is a silent but serious public health threat in Africa; millions are infected, yet most remain undiagnosed due to limited testing and awareness. Urgent action is needed: improved screening, education, and policy can save lives and stop the spread. 👉https://bit.ly/4qI00oW